华康洁净公告，公司股票于2025年7月29日、2025年7月30日、2025年7月31日连续3个交易日收盘价涨幅 偏离值累计超过30%，属于股票交易异常波动。公司自查并核实，发现近期公共传媒未报道可能或已经 对公司股票交易价格产生较大影响的未公开重大信息。公司目前经营情况及内外部经营环境未发生重大 变化，控股股东及实际控制人不存在应披露而未披露的重大事项，股票异常波动期间，控股股东及实际 控制人不存在买卖公司股票的行为。 ...

| 证券代码：301235 | 证券简称：华康洁净 | 公告编号：2025-086 | | --- | --- | --- | | 转债代码：123251 | 转债简称：华医转债 | | 武汉华康世纪洁净科技股份有限公司 股票交易异常波动公告 3、公司目前的经营情况及内外部经营环境未发生重大变化； 4、公司、控股股东和实际控制人不存在关于本公司的应披露而未披露的重大事 项，亦不存在处于筹划阶段的重大事项； 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、股票交易异常波动的具体情况 武汉华康世纪洁净科技股份有限公司（以下简称"公司"）股票（证券代码：301235， 证券简称：华康洁净）于 2025 年 7 月 29 日、2025 年 7 月 30 日、2025 年 7 月 31 日 连续 3 个交易日收盘价涨幅偏离值累计超过 30%，根据深圳证券交易所的有关规定， 属于股票交易异常波动的情况。 二、公司关注并核实情况 针对公司股票交易异常波动的情况，公司董事会就相关事项进行了自查，并向控 股股东、实际控制人进行了核实，现就相关情况说明如下： 1、公司前期披露 ...

转债代码：123251 转债简称：华医转债 证券代码：301235 证券简称：华康洁净 公告编号：2025-087 武汉华康世纪洁净科技股份有限公司 关于控股股东、实际控制人持有公司可转换公司债券变动 比例达到 10%的公告 注 2：本表数据合计数与各分项数值之和存在尾差系四舍五入造成。 经中国证券监督管理委员会《关于同意武汉华康世纪医疗股份有限公司向不 特定对象发行可转换公司债券注册的批复》(证监许可[2024]220 号)同意注册， 武汉华康世纪洁净科技股份有限公司（以下简称"公司"，曾用名"武汉华康世 纪医疗股份有限公司"）于 2024 年 12 月 23 日向不特定对象发行可转换公司债 券 750 万张，每张面值为 100 元，募集资金总额为人民币 750,000,000.00 元， 扣除承销及保荐费用、会计师、律师、资信评级及发行手续费等其他发行费用（不 含增值税）合计人民币 6,183,142.52 元后，实际募集资金净额为人民币 743,816,857.48 元。上述募集资金已于 2024 年 12 月 27 日到账，上述募集资金 到位情况已经中汇会计师事务所（特殊普通合伙）进行了审验，并于 2 ...

Core Viewpoint - Huakang Clean's half-year performance shows significant growth, with a strong increase in revenue and profit, indicating confidence in future performance through stock incentives [1] Group 1: Financial Performance - In H1 2025, the company reported revenue of 835 million (+50.7%) and net profit of 18.68 million (+273%) [1] - Q2 revenue reached 540 million (+66.45%) with a net profit of 47.64 million (+123.63%) [1] - The company has a backlog of orders amounting to 3.827 billion, primarily from purification integration business [1] Group 2: Business Segments - The order backlog includes 2.537 billion from medical special orders, 774 million from laboratory orders, and 121 million from electronic clean orders, showcasing a balanced business structure [1] - The electronic clean segment is expected to see rapid growth in the second half of the year, contributing to stable performance [1] Group 3: Market Outlook - The domestic clean market is projected to exceed 500 billion, with the electronic clean room market expected to reach 165.7 billion by 2024 [2] - The company is positioned in the first tier of the industry, leveraging its brand and technical expertise to enhance customer acquisition in the electronic clean market [2] Group 4: Profit Forecast and Valuation - EPS forecasts for 2025-2027 are 1.52, 2.18, and 3.14 yuan per share, with corresponding PE ratios of 21.85, 15.23, and 10.56 [3] - The company is rated as a "buy" based on its growth potential and market position [3]

证券研究报告：医药生物 | 公司点评报告 发布时间：2025-07-31 股票投资评级 买入 |上调 个股表现 2024-07 2024-10 2024-12 2025-03 2025-05 2025-07 -12% -2% 8% 18% 28% 38% 48% 58% 68% 78% 华康洁净 医药生物 资料来源：聚源，中邮证券研究所 公司基本情况 | 最新收盘价（元） | 33.19 | | --- | --- | | 总股本/流通股本（亿股）1.06 | / 0.71 | | 总市值/流通市值（亿元）35 | / 23 | | 52 周内最高/最低价 | 33.19 / 15.69 | | 资产负债率(%) | 57.3% | | 市盈率 | 52.68 | | 第一大股东 | 谭平涛 | 研究所 分析师:盛丽华 SAC 登记编号:S1340525060001 Email:shenglihua@cnpsec.com l 盈利预测与估值 预测 2025-2027 年 EPS 值分别为 1.52/2.18/3.14 元/股，现价对 应 PE 分别为 21.85/15.23/10.56 倍。给予"买入"评级。 ...

国浩律师（武汉）事务所 关 于 武汉华康世纪洁净科技股份有限公司 2025 年限制性股票激励计划（草案） 的 法律意见书 湖北省武汉市洪山区欢乐大道一号宏泰大厦 21 楼 邮编：430077 The 21st floor, Hongtai Building, No. 1 Huanle Avenue, Hongshan District, Wuhan city, Hubei Province, China 电话/Tel: (+86)(027) 87301319 传真/Fax: (+86)(027) 87265677 网址/Website:http://www.grandall.com.cn 2025 年 7 月 | | | | 释 义 … | | --- | | 第一节 律师声明事项 . | | 第二节 正 文 | | 一、公司实施本次激励计划的主体资格 | | 二、本次激励计划内容的合法合规性………………………………………………………………………………………………………………………………………………………………… 6 | | 三、本次激励计划所需履行的法定程序 | | 四、本次激励计划的激励对象确定依据及范围 ...

2025年7月30日，华康洁净(301235.SZ)发布2025年中报。 公司摊薄每股收益为0.19元。 公司最新总资产周转率为0.21次。最新存货周转率为1.06次，较去年同期存货周转率减少0.02次，同比较去年同期下降1.56%。 公司股东户数为9021户，前十大股东持股数量为6528.80万股，占总股本比例为61.83%，前十大股东持股情况如下： | 序号 | 股东名称 | 持股 | | --- | --- | --- | | l | 遭平涛 | 44.2. | | 2 | 阳光人寿保险股份有限公司-分红保险产品 | 5.31 | | 3 | 武汉康汇投资管理中心(有限合伙) | 4.56 | | 4 | 胡小艳 | 2.96 | | 5 | 陈海杰 | 1.80 | | 6 | 国联证券资管-浦发银行-国联华康医疗员工参与创业板战略配售集合资产管理计 划 | 0.66 | | 7 | BARCLAYS BANK PLC | 0.64 | | 8 | 招商银行股份有限公司-安信医药健康主题股票型发起式证券投资基金 | 0.62 | | 9 | J.P.Morgan Securities PLC-自有资金 ...

Group 1 - Huakang Clean (301235.SZ) released its semi-annual report for 2025 on July 30, 2025, with 10 institutional investors holding a total of 19.8267 million shares, accounting for 18.78% of the total share capital [1] - The top ten institutional investors include Sunshine Life Insurance Co., Ltd. - Dividend Insurance Product, Wuhan Kanghui Investment Management Center (Limited Partnership), and several others, with their combined holding ratio increasing by 0.56 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, one fund, Nuon An Multi-Strategy Mixed A, increased its holdings by 0.20%, while two new public funds were disclosed, including Anxin Medical Health Stock A and China Merchants CSI 1000 Index Enhanced A [2] - In the insurance capital sector, Sunshine Life Insurance Co., Ltd. - Dividend Insurance Product reduced its holdings by 1.0% compared to the previous quarter [2] - Three new foreign institutional investors were disclosed, including BARCLAYS BANK PLC, J.P. Morgan Securities PLC - proprietary funds, and Goldman Sachs LLC [2]

Core Insights - Huakang Clean (301235.SZ) reported a significant increase in revenue and net profit for the first half of the year, with revenue reaching 834.91 million yuan, a year-on-year growth of 50.73% [1] - The net profit attributable to shareholders was 18.68 million yuan, reflecting a remarkable year-on-year increase of 273.48% [1] - The company’s net profit after deducting non-recurring gains and losses was 19.60 million yuan, up 216.16% year-on-year [1] Financial Performance - The company experienced a net cash flow from operating activities of -294.27 million yuan, a decline of 74.03% compared to the previous year [1] - The weighted average return on net assets was 1.04%, an increase of 1.66% from the same period last year [1] - Total assets at the end of the reporting period were 3.78 billion yuan, a decrease of 10.57% from the beginning of the period [1] - The net assets attributable to shareholders were 1.75 billion yuan, down 2.86% from the start of the period [1] Business Segments - Revenue was primarily generated from purification system integration and medical consumables sales [1] - The company successfully delivered 22 projects during the reporting period [1] - As of the end of the reporting period, the company had an order backlog of 3.83 billion yuan, mainly from purification integration business, including 2.54 billion yuan in medical special orders, 774 million yuan in laboratory orders, and 121 million yuan in electronic clean orders, indicating a balanced structure among "medical special - laboratory - electronic clean" [1]

2024年1至12月份，华康洁净的营业收入构成为：医疗专项技术服务占比90.01%，医疗器械行业占比 9.27%，其他业务收入占比0.72%。 （文章来源：每日经济新闻） 华康洁净（SZ 301235，收盘价：27.66元）7月29日晚间发布公告称，本激励计划涉及的激励对象共计 204人，股票来源为公司向激励对象定向发行的本公司人民币A股普通股股票和/或从二级市场回购的本 公司人民币A股普通股股票；拟授予激励对象的限制性股票数量为523.58万股，约占公司截至2025年7月 25日公司股本总额约1.06亿股的4.96%；限制性股票的授予价格为每股18元，即满足授予条件和归属条 件后，激励对象可以每股18元的价格购买公司股票，的有效期为自限制性股票授予日起至激励对象获授 的限制性股票全部归属或作废失效之日止，最长不超过36个月。 ...